Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week High at $129.35

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $129.35 and last traded at $129.35, with a volume of 908 shares traded. The stock had previously closed at $124.45.

Analyst Ratings Changes

Several analysts have recently weighed in on ZLDPF shares. Cantor Fitzgerald began coverage on shares of Zealand Pharma A/S in a research report on Tuesday, May 21st. They set an “overweight” rating on the stock. BTIG Research started coverage on shares of Zealand Pharma A/S in a report on Thursday, March 7th. They set a “buy” rating for the company.

Zealand Pharma A/S Trading Up 3.9 %

The company has a market cap of $6.66 billion, a price-to-earnings ratio of -68.38 and a beta of 0.89. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.30 and a quick ratio of 12.28. The business has a 50 day simple moving average of $93.54 and a 200 day simple moving average of $82.46.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, May 16th. The company reported ($0.54) earnings per share (EPS) for the quarter. The company had revenue of $2.20 million for the quarter. Zealand Pharma A/S had a negative return on equity of 36.96% and a negative net margin of 213.77%. As a group, equities analysts forecast that Zealand Pharma A/S will post -2.54 EPS for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.